Literature DB >> 9378534

In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).

K Csóka1, B Tholander, E Gerdin, M de la Torre, R Larsson, P Nygren.   

Abstract

The fluorometric microculture cytotoxicity assay (FMCA), a short-term in vitro assay based on the concept of total tumor cell kill, was used for testing the cytotoxic drug sensitivity of tumor cells from patients with ovarian carcinoma. A total of 125 fresh specimens was obtained, 98 (78%) of which were analyzed successfully. Data from 45 patients were available for clinical correlations. The FMCA appeared to yield clinically relevant cytotoxic drug sensitivity data for ovarian carcinoma as indicated by a comparison with tumor samples obtained from patients with non-Hodgkin's lymphoma or kidney carcinoma. Considering the most active single agent in vitro actually given in vivo, and using the median drug activity among all ovarian carcinoma samples as a cut-off, the sensitivity of the assay and its specificity were 75 and 52%, respectively. Cross-resistance in vitro was frequently observed between standard drugs but not between standard drugs and Taxol. Ten percent of the specimens showed an extreme resistance for at least 4 of 6 of the drugs investigated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378534     DOI: 10.1002/(sici)1097-0215(19970917)72:6<1008::aid-ijc15>3.0.co;2-0

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Authors:  Ake Berglund; Bengt Glimelius; Jonas Bergh; Ola Brodin; Marie-Louise Fjällskog; Hans Hagberg; Anne von Heideman; Rolf Larsson; Bengt Tholander; Manuel de la Torre; Gunnar Aström; Kjell Oberg; Gunnar Parö; Peter Nygren
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  In vitro chemosensitivity testing and mechanisms of drug resistance.

Authors:  K Tewari; A Manetta
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

3.  In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.

Authors:  M Kashif; C Andersson; S Hassan; H Karlsson; W Senkowski; M Fryknäs; P Nygren; R Larsson; M G Gustafsson
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

4.  Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.

Authors:  Kathrine Bjersand; Haile Mahteme; Inger Sundström Poromaa; Håkan Andréasson; Wilhelm Graf; Rolf Larsson; Peter Nygren
Journal:  Ann Surg Oncol       Date:  2015-07-21       Impact factor: 5.344

5.  Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy.

Authors:  Bo Hultman; Haile Mahteme; Magnus Sundbom; Martin Ljungman; Rolf Larsson; Peter Nygren
Journal:  J Exp Clin Cancer Res       Date:  2014-12-21

6.  Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Authors:  Henning Karlsson; Mårten Fryknäs; Sara Strese; Joachim Gullbo; Gunnar Westman; Ulf Bremberg; Tobias Sjöblom; Tatjana Pandzic; Rolf Larsson; Peter Nygren
Journal:  Oncotarget       Date:  2017-05-02

7.  Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer.

Authors:  Peter H Cashin; Haile Mahteme; Wilhelm Graf; Henning Karlsson; Rolf Larsson; Peter Nygren
Journal:  BMC Cancer       Date:  2013-09-24       Impact factor: 4.430

Review 8.  Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.

Authors:  Manfred Volm; Thomas Efferth
Journal:  Front Oncol       Date:  2015-12-17       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.